Serum concentrations of apoiipoprotein(a) [apo(a)], the unique glycoprotein of lipoprotein(a), are increased in patients with end-stage renal failure. We prospectively studied serum apo(a) and other lipoproteinsin 20 consecutive patients, ages 46 ± 11 years, before and for six months after successful renal transplantation. All patients received cyclosporine, and no patient was treated for hyperlipidemia. The mean creatinine clearance increased from 7.5 mLimin before transplant surgery to 40.9 mLlmin six months afterwards (P <0.001). Apo(a) decreased from a median of 403 units/L before transplantationto 184 units/L at one week (P <0.001) and was 170 units/L (P <0.001) at six months. For the assay used, 1 unit of apo(a) is equivalent to 1 mg of lipoprotein(a). In contrast, from baseline to six months, increases were found for low-density lipoprotein (LDL) cholesterol (P = 0.03), high-density lipoprotein cholesterol (P = 0.06), apo B (P mediating the increase in apo(a) concentrations in patients undergoing renal dialysis are not known, and the effect on apo(a) concentrations of improved renal function after renal transplantation has not been reported. To examine the effects of renal transplantation on serum apo(a) concentrations in patients with end-stage renal failure, we prospectively studied a consecutive series of patients with end-stage renal failure before and after successful renal transplantation.
nary artery disease, similar to and synergistic with LDL cholesterol (10, 11), and possibly with an increased risk of thrombosis (9) . Lp(a) has been shown to accumulate in atherosclerotic lesions of coronary bypass grafts and native coronary homology of apo(a) with plasminogen and is supported by in vitro and in vivo evidence (9, 13) .
Recent studies indicate that Lp(a) concentrations in apparentlynormal subjects are related to the apo(a) phenotype, which is determined by a series of autosomal alleles at the apo(a) gene locus (14) , and that apo(a) is produced in the liver (15) . One of the striking properties of Lp(a) metabolism is the stability of Lp(a) concentrations in individual patients, being correlated in normal subjects with the rate of Lp(a) synthesis rather than with the rate of catabolism (16). Little is known, however, about alterations in Lp(a) concentrations in conditions known to be associated with abnormal lipoprotein metabolism, e.g., renal disease. The mechanism(s) mediating the increase in apo(a) concentrations in patients undergoing renal dialysis are not known, and the effect on apo(a) concentrations of improved renal function after renal transplantation has not been reported. To examine the effects of renal transplantation on serum apo(a) concentrations in patients with end-stage renal failure, we prospectively studied a consecutive series of patients with end-stage renal failure before and after successful renal transplantation.
Patients and Methods

Patients
At one institution, 26 consecutive adult patients undergoing renal transplantation for end-stage renal failure were initially enrolled in the study. All patients received cadaveric kidney grafts. Six patients underwent graft nephrectomy within one month of transplantation and were excluded from further analysis. Renal transplantation was successful in the remaining 20 patients, and in these patients dialysis was not required six weeks after the surgery.
The study population was 10 men and 10 women, mean age 46 (range 24-58) years. All patients were undergoing dialysis before transplantation, seven by chronic ambulatory peritoneal dialysis and 13 by hemodialysis. The mean duration of dialysis was 26 (range 1-120) months. The etiology of renal failure, as determined by renal biopsy, was glomerulonephritis (n = 8), analgesic nephropathy (n = 4), reflux nephropathy (n = 4),polycystic disease (n = 2), diabetes mellitus (n = 1), 
and other values as mean (SD).
Results
Lipoprotein concentrations
and creatinine clearance before and after transplantation are shown in Table 1 . Ape(a) decreased significantly between baseline and one week after surgery (P <0.001) and again between one week and one month (P = 0.002). We noted a small increase from one to six months (P = 0.006), which patients (55%) at baseline. A single patient in the series developed nephrotic syndrome after transplantation; no other patient had >2 g/day proteinuria. This 48-year-old man with membrano-proliferative glomerulonephritis had undergone hemodialysis for 18 months before transplantation.
Nephrotic syndrome developed in the first month alter surgery and was shown by renal biopsy to be due to recurrent glomerulonephritis.
The development of proteinuria was associated with marked increases in ape(a) (Figure 1 ), total and LDL cholesterol, and ape B (Table  2) . Two other patients without significant proteinuria (<0.2 g/day) had modest increases in apo(a) during the study period-from 590 to 635 unitsfL in one patient and from 130 to 181 units/L in the other.
There was no significant correlation between apo(a) We assessed the correlation between changes in renal function and ape(a) concentrations from the percentage changes in creatinine clearance and in ape(a) concentrations in each patient during the pre-and post-transplant periods. We found a highly significant relationship (r = -0.48, P <0.001).
We compared patients with clinically significantly increased concentrations of apo(a) before transplantation, defined as >300 unitsfL apo(a), i.e., >300 mg/L Lp(a) (10, 11) , and the remaining patients [ and at six months (3.29 vs 3.34) , nor was the ape B/ape A-I ratio (0.99 vs 1.00).
We also assessed the correlation between cumulative immunosuppressant dose adjusted for body weight (mg/ kg) and lipoprotein concentrations during the post- 
Discussion
Since Lindner et al.
(1) reported in 1974 that cardiovascular disease is a major cause of death in chronic dialysis patients, the possible relationship between the lipoprotein abnormalities associated with chronic renal failure and atherogenesis has been studied extensively (20) . It has proved difficult to explain the increased cardiovascular risk by contributions from abnormal lipid concentrations and other recognized risk factors The major finding of the present study was a large reduction in apo(a) concentrations after renal transplantation, with a decline to values slightly higher than in the normal population. We saw this reduction in 17 of the 20 patients; moreover, it was apparent within one month after transplantation and was maintained throughout the six-month study period. The early decline in apo(a) concentrations was particularly striking because Lp(a) values in normal subjects are reported to increase for as long as one month after surgical procedures (24). We also found a significant correlation between the change in renal function and apo(a) values but no correlation between ape(a) and ape B or ape A-I. These findings are consistent with a relationship between abnormal renal function and the regulation of Lp(a) metabolism.
The kidney itself has not been reported to participate directly in ape(a) metabolism. However, hepatic production of apo(a) correlates with apo(a) concentrations in normal subjects (16), and it is possible that this is stimulated by the metabolic derangements of end-stage renal failure. Catabolism of apo(a) could also be impaired in renal failure. Neary and Gowland ( Factors in the pest-transplant state other than improved renal function, e.g., immunosuppressive drug therapy, could also contribute to the decline in concentrations of apo(a). However, we found no correlation between immunosuppressants dosage and ape(a) concentrations; also, the high concentrations pre-transplant cannot be due to immunosuppressive drug therapy. Moreover, cyclosporine is associated with increases in ape B and LDL cholesterol (26), in contrast with the decline in ape(a) that we observed.
Of particular interest was the dramatic and parallel increase of apo(a) and proteinuria in the one patient who developed nephrotic syndrome, because this event may provide insight into the mechanism of the initial increase in concentrations of apo(a). It is relevant that the only patient in whom nephrotic syndrome developed after transplantation was also the only patient in whom there was a marked increase in apo(a) (Figure 1) , and that this occurred in association with an increase in the other ape B-containing lipoproteins.
Increased serum reported that nicotinic acid resulted in a marked reduction in Lp(a) concentrations, which was highly correlated (r = 0.88) with the reduction in LDL cholesterol. They argued that this correlation arose from inhibition of the synthesis of ape B, which is common to the two lipoproteins. In the present study, pre-transplant concentrations of ape B, LDL cholesterol, and ape(a) were higher in patients treated with peritoneal dialysis than in those managed by hemodialysis. Sniderman et al. (33) showed that these differences for ape B and LDL cholesterol are due to increased ape B production with peritoneal dialysis. Although the higher apo(a) in patients treated with peritoneal dialysis in the present series was not statistically significant, the trend is consistent with an increase in apo(a) due to increased production.
The relatively small number of patients studied limits our analysis of the complex factors in the pest-renaltransplant state, which may influence ape(a) concentrations. However, the prospective nature of the study, with each patient as his or her own control, strengthens the validity of the major finding of a large reduction in ape(a) concentrations after transplantation. These results are consistent with a relationship between improved renal function after transplantation and a reduction in previously increased apo(a) values. Increased hepatic production of Lp(a) appears to be the most likely mechanism of the increased apo(a) concentrations associated with renal failure, although the evidence is indirect. Our findings have implications for the regulation of Lp(a) metabolism and for the etiology of vascular disease in patients with abnormal renal function. Further investigation with determination of apo(a) phenotypes and apo(a) turnover studies in patients with renal disease is required.
We thank the members of the Department of Nephrology for permitting study of their patients; Dr. Andrew Hopkins for constructing the computer database; and Sue Khouri, Aviva Green, and Carolyn Nelson for performing apolipoprotein assays.
